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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications of phase III trials, assessing the 
safety and efficacy of the drugs of interest. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), nine information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every three months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies five prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 38th prioritisation (January 2019), ten drugs were filtered out of 502 identified and were sent to 
prioritisation. Of these, three drugs were ranked as ‘highly relevant’ by the expert panel, seven as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
No Filtered Drugs – 38
th
 prioritisation 1
st
 quarter 2019 Overall category 
1. Atezolizumab (Tecentriq
®) and nab-paclitaxel in advanced triple-
negative breast cancer  Highly relevant 
2. First-line atezolizumab (Tecentriq
®) plus chemotherapy in 
extensive-stage small-cell lung cancer (SCLC) Relevant 
3. Brigatinib (Alunbrig®) versus crizotinib in ALK-positive NSCLC Relevant 
4. Pembrolizumab (Keytruda
®) plus chemotherapy for squamous 
NSCLC Highly relevant 
5. 
Frontline bortezomib (Velcade®), rituximab, cyclophosphamide, 
doxorubicin, and prednisone (VR-CAP) versus rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) in transplantation-ineligible patients with newly diagnosed 
mantle cell lymphoma (MCL) 
Relevant 
6. 
Duvelisib (Copiktra®) versus ofatumumab in relapsed and 
refractory (RR) chronic lymphocytic leukemia (CLL)/ small 
lymphocytic lymphoma (SLL) 
Relevant 
7. 
Addition of lomustine (Gleostine®) to conventional chemotherapy 
for elderly patients with acute myeloid leukaemia (AML) without 
unfavorable cytogenetics 
Relevant 
8. Elotuzumab (Empliciti
®) plus pomalidomide and dexamethasone 
for MM Relevant 
9. Maintenance olaparib (Lynparza
®) in patients with newly 
diagnosed advanced ovarian cancer Highly relevant 
10. Trifluridine/tipiracil (TAS-102, Lonsurf
®) versus placebo in patients 
with heavily pretreated metastatic gastric cancer Relevant 
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Breast Cancer 
Atezolizumab (Tecentriq®) and nab-paclitaxel in advanced triple 
negative breast cancer 
Overview 
Drug Description 
atezolizumab selectively targets programmed death ligand 1 (PD-L1) to 
prevent interaction with the receptors PD-1 and B7-1 (a co-stimulatory cell-
surface protein), reversing T-cell suppression 
Patient Indication patients with untreated metastatic triple-negative breast cancer 
Incidence in 
Austria  
breast cancer: 5,480 newly diagnosed per year (2015), 116.7/100,000 
women/year (2015) (European Standard Population 2013) [1] 
Ongoing Phase III 
NCT02425891(IMpassion 130) until 04/2020 
NCT03125902 until 06/2021 
NCT03281954 until 06/2024 
NCT03498716 until 12/2024 
NCT03371017 until 01/2021 
Approval 
status for 
this 
indication 
[2, 3] 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
[2, 3] 
EMA 
according to product information (09/2018) atezolizumab is indicated 
a as monotherapy for the treatment of adult patients with locally 
advanced or metastatic urothelial carcinoma (UC) 
- after prior platinum-containing chemotherapy, or  
- who are considered cisplatin ineligible, and whose tumours 
have a PD-L1 expression ≥ 5% 
a as monotherapy for the treatment of adult patients with locally 
advanced or metastatic non-small cell lung cancer (NSCLC) after 
prior chemotherapy. Patients with epidermal growth factor 
receptor (EGFR) activating mutations or anaplastic lymphoma 
kinase (ALK)-positive tumour mutations should also have received 
targeted therapy before receiving atezolizumab. 
FDA 
according to label information (12/2018) atezolizumab is indicated in 
a UC: 
- for the treatment of patients with locally advanced or 
metastatic UC who are not eligible for cisplatin-containing 
chemotherapy and whose tumors express PD‐L1 (PD-L1 
stained tumor-infiltrating immune cells [IC] covering ≥ 5% of 
the tumor area), as determined by an FDA-approved test, or 
who are not eligible for any platinum‐containing chemotherapy 
regardless of PD‐L1 status, or who have disease progression 
during or following any platinum-containing chemotherapy, or 
within 12 months of neoadjuvant or adjuvant chemotherapy  
(indication is approved under accelerated approval) 
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a NSCLC: 
- in combination with bevacizumab, paclitaxel, and carboplatin,  
for the first-line treatment, of patients with metastatic non- 
squamous NSCLC with no EGFR or ALK genomic tumor  
aberrations 
- for the treatment of patients with metastatic NSCLC who have 
disease progression during or following platinum-containing 
chemotherapy. Patients with EGFR or ALK genomic tumor 
aberrations should have disease progression on FDA-
approved therapy for NSCLC harboring these aberrations prior 
to receiving atezolizumab.  
Costs  
Tecentriq® is available as concentrate for solution for infusion (1200 mg) at 
€ 4,799.20 (ex-factory price) [4].  
 
Impassion 130 patients received atezolizumab at a dose of 840 mg or 
placebo, administered intravenously (IV), on days 1 and 15 of every 28-
day cycle -> € 9,598.4/cycle. Median duration of atezolizumab treatment 
among Impassion 130 patients was 24.1 weeks -> approx. 57,590.4 for 6 
months of atezolizumab treatment. 
In addition, costs for nab-paclitaxel incur. 
1.1.1 Published articles (PubMed): 
NEJM; available online October 20, 2018 (Schmid et al.): “Atezolizumab and nab-paclitaxel in 
advanced triple-negative breast cancer” [5] 
Background  
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human 
epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor 
outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of 
atezolizumab. 
 
Methods  
In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-
negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; 
patients continued the intervention until disease progression or an unacceptable level of toxic effects 
occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane 
therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 
(PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-
free survival (in the intention-to-treat population and PD-L1–positive subgroup) and overall survival 
(tested in the intention-to-treat population; if the finding was significant, then it would be tested in the 
PD-L1–positive subgroup). 
 
Findings  
Each group included 451 patients (median follow-up, 12.9 months). In the intention to-treat analysis, 
the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as 
compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 
0.80; 95% confidence interval [CI], 0.69 to 0.92; P = 0.002); among patients with PD-L1–positive 
tumors, the median progression- free survival was 7.5 months and 5.0 months, respectively (hazard 
ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall 
survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus 
nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P = 0.08); among patients with PD-
L1–positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively 
(hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that 
led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab 
plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. 
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Interpretation  
Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic 
triple-negative breast cancer in both the intention-to-treat population and the PD-L1–positive 
subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. 
Hoffmann–La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891. 
Lung Cancer 
Pembrolizumab (Keytruda®) plus chemotherapy for squamous 
NSCLC 
Overview 
Drug Description PD-1 inhibitor 
Patient Indication 
patients with stage IV squamous NSCLC who had received no previous 
systemic therapy for metastatic disease 
Incidence in 
Austria  
4,860 newly diagnosed per year (2015), 57.9/100,000 persons/year (2015) 
(European Standard Population 2013) including lung, trachea and 
bronchial tumours [6] 
Ongoing Phase III 
NCT02775435 (KEYNOTE-407) until 02/2021 
NCT03631199 until 10/2022 
NCT03515629 until 03/2023 
Approval 
status for 
this 
indication 
[2, 3] 
EMA - 
FDA 
10/2018: pembrolizumab, in combination with carboplatin and either 
paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of 
patients with metastatic squamous NSCLC  
Approval 
status for 
other 
indications 
[2, 3] 
EMA 
pembrolizumab is indicated: 
- as monotherapy for the treatment of advanced (unresectable 
or metastatic) melanoma in adults. 
- as monotherapy for the first-line treatment of metastatic 
NSCLC in adults whose tumours express PD-L1 with a ≥ 50% 
tumour proportion score (TPS) with no EGFR or ALK positive 
tumour mutations. 
- in combination with pemetrexed and platinum chemotherapy, 
for the first-line treatment of metastatic non-squamous NSCLC 
in adults whose tumours have no EGFR or ALK positive 
mutations. 
- as monotherapy is for the treatment of locally advanced or 
metastatic NSCLC in adults whose tumours express PD-L1 
with a ≥ 1% TPS and who have received at least one prior 
chemotherapy regimen. Patients with EGFR or ALK positive 
tumour mutations should also have received targeted therapy 
before receiving pembrolizumab. 
- as monotherapy for the treatment of adult patients with 
relapsed or refractory classical Hodgkin lymphoma (cHL) who 
have failed autologous stem cell transplant (ASCT) and 
brentuximab vedotin (BV), or who are transplant-ineligible and 
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have failed BV. 
- as monotherapy for the treatment of locally advanced or 
metastatic UC in adults who have received prior platinum-
containing chemotherapy. 
- as monotherapy for the treatment of locally advanced or 
metastatic UC in adults who are not eligible for cisplatin-
containing chemotherapy and whose tumours express PD L1 
with a combined positive score (CPS) ≥ 10. 
- as monotherapy for the treatment of recurrent or metastatic 
head and neck squamous cell carcinoma (HNSCC) in adults 
whose tumours express PD-L1 with a ≥ 50% TPS and 
progressing on or after platinum-containing chemotherapy. 
In October 2017, the manufacturer officially notified the Committee for 
Medicinal Products for Human Use (CHMP) that it wishes to withdraw its 
application to extend the use of pembrolizumab in NSCLC to include 
metastatic non-squamous NSCLC in combination with chemotherapy. 
Pembrolizumab was also expected to be used in combination with the 
chemotherapy medicines pemetrexed and carboplatin in NSCLC patients 
with metastatic non-squamous NSCLC, irrespective of whether their 
tumour produced the PD-L1 protein. 
FDA 
pembrolizumab is indicated in  
• melanoma: for the treatment of patients with unresectable or 
metastatic melanoma 
• NSCLC:  
- in combination with pemetrexed and platinum chemotherapy, 
as first-line treatment of patients with metastatic nonsquamous  
NSCLC, with no EGFR or ALK genomic tumor aberrations.  
- as a single agent for the first-line treatment of patients with  
metastatic NSCLC whose tumors have high PD-L1 expression 
[TPS ≥50%] as determined by an FDA-approved test, with no 
EGFR or ALK genomic tumor aberrations.  
- as a single agent for the treatment of patients with metastatic  
NSCLC whose tumors express PD-L1 (TPS ≥1%) as  
determined by an FDA-approved test, with disease 
progression on or after platinum-containing chemotherapy. 
Patients with EGFR or ALK genomic tumor aberrations should 
have disease progression on FDA-approved therapy for these 
aberrations prior to receiving pembrolizumab. 
• HNSCC: 
- for the treatment of patients with recurrent or metastatic 
HNSCC with disease progression on or after platinum-
containing chemotherapy. 
• cHL: 
- for the treatment of adult and pediatric patients with refractory 
cHL, or who have relapsed after 3 or more prior lines of 
therapy. 
• primary mediastinal large B-cell lymphoma (PMBCL): 
- for the treatment of adult and pediatric patients with refractory 
PMBCL, or who have relapsed after 2 or more prior lines of 
therapy. Limitation of Use: pembrolizumab is not 
recommended for treatment of patients with PMBCL who 
require urgent cytoreductive therapy. 
• UC:  
- for the treatment of patients with locally advanced or 
metastatic UC who are not eligible for cisplatin-containing 
chemotherapy and whose tumors express PD-L1 [Combined 
Positive Score (CPS) ≥10] as determined by an FDA-
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approved test, or in patients who are not eligible for any 
platinum-containing chemotherapy regardless of PD-L1 status. 
- for the treatment of patients with locally advanced or 
metastatic UC who have disease progression during or 
following platinum-containing chemotherapy or within 12 
months of neoadjuvant or adjuvant treatment with platinum-
containing chemotherapy.  
• Microsatellite Instability-High Cancer: 
- for the treatment of adult and pediatric patients with 
unresectable or metastatic, microsatellite instability-high (MSI-
H) or mismatch repair deficient solid tumors that have 
progressed following prior treatment and who have no 
satisfactory alternative treatment options, or colorectal cancer 
that has progressed following treatment with a 
fluoropyrimidine, oxaliplatin, and irinotecan. Limitation of Use: 
The safety and effectiveness of pembrolizumab in pediatric 
patients with MSI-H central nervous system cancers have not 
been established.  
• Gastric Cancer: 
- for the treatment of patients with recurrent locally advanced or  
metastatic gastric or gastroesophageal junction 
adenocarcinoma whose tumors express PD-L1 [CPS ≥1] as 
determined by an FDA-approved test, with disease 
progression on or after two or more prior lines of therapy 
including fluoropyrimidine- and platinum-containing 
chemotherapy and if appropriate, HER2/neu-targeted therapy. 
• Cervical Cancer: for the treatment of patients with recurrent or 
metastatic cervical cancer with disease progression on or after 
chemotherapy whose tumors express PD-L1 (CPS ≥1) as 
determined by an FDA-approved test. 
• Hepatocellular Carcinoma (HCC): for the treatment of patients with 
HCC who have been previously treated with sorafenib. 
Costs  
Keytruda® 50 mg powder for concentrate for solution for infusion = € 
1,714.00 (ex-factory price) [4]. 
KEYNOTE-407 patients received 200 mg of pembrolizumab (€ 6,856.00/ 
per dose) or placebo on day 1 for up to 35 3-week cycles.  
In addition (for the first 4 cycles) costs for carboplatin and either paclitaxel 
or nab-paclitaxel incur. The patients who received paclitaxel also received 
premedication with a glucocorticoid, a type 1 antihistamine, and a type 2 
antihistamine according to local guidelines. 
1.1.2 Published articles (PubMed): 
NEJM; available online September 25, 2018 (Paz-Ares et al.): “Pembrolizumab plus chemotherapy 
for squamous non–small-cell lung cancer” [7] 
Background  
Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-
based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] 
expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to 
significantly prolong overall survival among patients with nonsquamous NSCLC. 
 
Methods  
In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated 
metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 
cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound 
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[nab]–paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free 
survival. 
 
Findings  
After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence 
interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 
9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; 
P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The 
median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-
combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio 
for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or 
higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the 
patients in the placebo-combination group. Discontinuation of treatment because of adverse events 
was more frequent in the pembrolizumab-combination group than in the placebo-combination group 
(13.3% vs. 6.4%). 
 
Interpretation  
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to 
chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall 
survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; 
KEYNOTE-407 ClinicalTrials.gov number, NCT02775435.) 
Ovarian Cancer 
Maintenance olaparib (Lynparza®) in patients with newly diagnosed 
advanced ovarian cancer 
Overview 
Drug Description an oral poly(adenosine diphosphate–ribose) polymerase inhibitor 
Patient Indication 
patients with newly diagnosed advanced (International Federation of 
Gynecology and Obstetrics stage III or IV) high-grade serous or 
endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube 
cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, 
or both (BRCA1/2) who had a complete or partial clinical response after 
platinum-based chemotherapy. 
Incidence in 
Austria  
ovarian cancer: 659 newly diagnosed per year (2015), 14.1/100,000/year 
(2015) (European Standard Population 2013) [8] 
Ongoing Phase III 
NCT01844986 (SOLO-1) until 06/2023 
NCT02477644 until 06/2022 
NCT03737643 until 07/2025 
NCT03740165 until 08/2025 
Approval 
status for 
this 
indication 
[2, 3] 
EMA 
05/2018 (extension of indication): olaparib is indicated as monotherapy for 
the maintenance treatment of adult patients with platinum -sensitive 
relapsed BRCA-mutated (germline and/or somatic) high grade serous 
epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in 
response (complete response or partial response) to platinum -based 
chemotherapy.  
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FDA - 
Approval 
status for 
other 
indications 
[2, 3] 
EMA - 
FDA 
olaparib is indicated for the treatment of adult patients with deleterious or 
suspected deleterious germline BRCA-mutated advanced ovarian cancer 
who have been treated with three or more prior lines of chemotherapy.  
Costs  
112 Lynparza tablets (150 mg) = € 5,059.29 [4] 
 
Patients of SOLO-1 trial received olaparib tablets (300 mg twice 
daily) or placebo. Based on this dosing regimen, 28 days of olaprib 
treatment would cost € 5,059.29. The median duration of the trial 
intervention in the olaparib group was 24.6 months -> approx. € 
124,458.53. 
1.1.3 Published articles (PubMed): 
NEJM; available online October 21, 2018 (Moore et al.): “Maintenance olaparib in patients with 
newly diagnosed advanced ovarian cancer” [9] 
Background  
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after 
standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral 
poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well 
established, but the benefit of olaparib as maintenance therapy in newly diagnosed disease is 
uncertain. 
 
Methods  
We conducted an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of 
olaparib as maintenance therapy in patients with newly diagnosed advanced (International Federation 
of Gynecology and Obstetrics stage III or IV) high-grade serous or endometrioid ovarian cancer, 
primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in 
BRCA1, BRCA2, or both (BRCA1/2) who had a complete or partial clinical response after platinum-
based chemotherapy. The patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets 
(300 mg twice daily) or placebo. The primary end point was progression- free survival. 
 
Findings  
Of the 391 patients who underwent randomization, 260 were assigned to receive olaparib and 131 to 
receive placebo. A total of 388 patients had a centrally confirmed germline BRCA1/2 mutation, and 2 
patients had a centrally confirmed somatic BRCA1/2 mutation. After a median follow-up of 41 months, 
the risk of disease progression or death was 70% lower with olaparib than with placebo (Kaplan–Meier 
estimate of the rate of freedom from disease progression and from death at 3 years, 60% vs. 27%; 
hazard ratio for disease progression or death, 0.30; 95% confidence interval, 0.23 to 0.41; P<0.001). 
Adverse events were consistent with the known toxic effects of olaparib. 
 
Interpretation  
The use of maintenance therapy with olaparib provided a substantial benefit with regard to 
progression-free survival among women with newly diagnosed advanced ovarian cancer and a 
BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with 
placebo. (Funded by AstraZeneca and Merck; SOLO1 ClinicalTrials.gov number, NCT01844986.) 
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